Business Wire

EMG Announces Appointment of Shaun Gregory as New Group Chief Executive Officer

Share

EMG, a leading global provider of broadcast facilities and media solutions, announced today that Shaun Gregory will join the company as Group Chief Executive Officer starting May 17th 2021. Gregory is a seasoned executive with over 30 years of experience in the media, telecommunications & broadcasting industries. He has served as Chief Executive Officer for some of the fastest growing companies, both in Europe and globally.

Under his leadership, EMG will continue the development of its ambitious transformation strategy. He will succeed co-CEO Patrick van den Berg who after 15 years serving in various leadership positions at EMG will take on a new professional challenge while co-CEO François-Charles Bideaux will become advisor to the CEO & EMG board focusing on specific areas such as sales, technology and M&A.

Most recently, Gregory was CEO of media localization company IYUNO Media Group (formerly BTI Studios) which spans 46 countries and 88 language types, servicing the world’s leading entertainment brands, including Netflix and Disney. In this role, he was responsible for developing a market leading strategy, transforming the business and the creation of a new global market leader in media localisation. Prior to IYUNO, Gregory was Chief Executive Officer at Exterion Media, Europe’s largest privately held out of home advertising company. At Exterion Media, Shaun was appointed Chief Executive in 2014, and was successfully awarded the world’s biggest outdoor advertising contract, The London Underground. Exterion operated across markets in Europe, including the UK, Ireland, Netherlands, France and Spain. Both companies enjoyed market beating growth under private equity ownership, with Exterion sold to Global in 2018.

Prior to IYUNO and Exterion, Gregory was the Global Managing Director of Telefonica’s media and content businesses. He was responsible for 34 markets, including most of Latin America, having emerged out of his UK role at O2. He was credited with a number of launches, including O2 Priority in the UK, and created new and innovative ways of delivering content to consumers. Before his time at Telefonica he spent almost 15 years at EMAP, Europe’s fastest growing media company where he was a key architect in the company’s digital transformation, winning several licences (analogue and digital), spanning radio and television. In addition, EMAP was pivotal in the launch of the UK’s digital terrestrial television platform Freeview.

Patrick van den Berg commented: “First of all a warm welcome to Shaun. After my 15 years in different leadership positions within EMG and finally as co-CEO, it is important for me that a seasoned executive with a broad and international experience takes over as CEO. Given Shaun’s background I am confident that he will lead EMG into future successes. I would like to take this opportunity to thank everybody at EMG as well as our founders and investors, for everything we realized and for the group we built together. It has been a great adventure and although it is time for me to take on a new professional challenge, I will surely keep on following the amazing company which is EMG.”

“On behalf of the board of EMG, I would like to thank Patrick for his contribution in making EMG the success it is today and wish him all the best in his next challenge,” added Fabrice Fouletier, Partner at PAI Partners, the majority shareholder in EMG. “We are thrilled to have appointed someone with Shaun’s credentials. He has an excellent track record, that spans over 30 years, in both listed and private equity backed companies. He has operated at the most senior level of some of the fastest growing companies in our sector and has done that successfully through innovation and a relentless focus on growth. His international and transformation experience will provide a strong platform for EMG, and I am confident that he will lead the company into a new and exciting chapter.”

Shaun Gregory said: “I’m excited to be joining the EMG Team, and can’t wait to continue the great work that’s been going on there. I see these as pivotal moments in the broadcasting and live events industry. As the world returns to normality, the appetite for what EMG delivers to people around the globe will become ever more important. EMG have played an acute role in getting people through the challenges of the pandemic, delivering some of the world’s most prestigious sporting events. As we look forward to happier times, I’m thrilled to be part of a new growth story and delivering the raw emotions and experiences to audiences around the world.”

He added: “The industry will need to innovate with new technological solutions, and EMG are already leading the way. Our customers and partners will have changing needs, as the landscape develops, and I’m looking forward to us being ahead of the curve. It’s not just about innovation, it’s also about taking a very ‘customer-centric’ approach to everything we do, and that’s one thing that EMG is all about – great customer service, innovation and ultimately a world class delivery. I’m very proud to be joining the Team, and providing the Leadership for the next chapter.”

Gregory has also served as a non-Executive Director of both listed and private equity backed companies. He also serves on the Childline Board (NSPCC) and the Advisory Board for The Sheffield Children’s Hospital. He is originally from Yorkshire in the UK, has two daughters and currently lives in London.

About EMG

EMG is a leading global provider of broadcast services and media solutions for live sports, entertainment and events, active in 10 countries: France, Belgium, the Netherlands, Germany, United Kingdom, Switzerland, Italy, Luxembourg, the USA & Australia. Constantly proposing state-of-the-art technologies through highly experienced teams, EMG is a valued partner for major international events, including sport (Tour de France, Football World Cup and Formula One…) live events (Eurovision, Royal Weddings, Concerts…) and entertainment (The Voice, Masterchef, the X-Factor…).

www.emglive.com

About PAI Partners

PAI Partners is a leading European private equity firm with offices in Paris, London, Luxembourg, Madrid, Milan, Munich, New York and Stockholm. It manages €14.7 billion of dedicated buyout funds and, since 1994, has completed 84 transactions in 11 countries, representing over €60 billion in transaction value. PAI Partners is characterised by its industrial approach to ownership combined with its sector-based organisation. It provides the companies it owns with the financial, operational and strategic support required to pursue their development and enhance value creation.

www.paipartners.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Pauline Bénéat
pauline.beneat@emglive.com
+32 (0) 472 188 495

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sky Labs Finalizes Series B Round Successfully Planning to Take Over Global Markets21.6.2021 15:00:00 CEST | Press release

Attracting USD 20 million investment, Sky Labs (CEO: Jack Lee), a global health care start-up, finalized Series B Round successfully. The accumulated amount of investment Sky Labs has attracted is USD 30 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005004/en/ Sky Labs, a global health care start-up, finalizes Series B Round successfully attracting USD 20 million investment. The accumulated amount of investment is USD 30 million. Sky Labs developed CART-I, the world’s first AI-based ring-type heart monitoring platform. It consists of a ring-type wearable medical device and user’s application and medical professional’s web platform and enables atrial fibrillation patients to conduct monitoring when they are not in a hospital. In addition, the photoplethysmography (PPG) sensor in the ring monitors the bloodstream in the finger to measure irregular pulse waves. The measured data are transmitted to a cloud platfo

Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the Significant Under-Diagnosis of Migraine21.6.2021 14:01:00 CEST | Press release

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today presented new epidemiology data on migraine from the State of Israel which indicate that socio-economic factors may contribute to underdiagnosis of migraine across society1. A retrospective study of migraine epidemiology in Southern Israel, supported by Teva and presented at the virtual 7th Congress of the European Academy of Neurology (EAN), found extreme variability in the prevalence of diagnosed patients with migraine across the geographic area studied. Prevalence rates were positively associated with the socio-economic status of the geographic area studied, suggesting that those living with migraine from less advantaged areas may find it harder to achieve an accurate diagnosis and thereby access appropriate therapy. “These findings are concerning not least because they suggest significant ‘migraine awareness inequity’ in this population,” said Professor Gal Ifergane, study investigator, practitioner, head of the Depart

New Data Supporting the Safety and Efficacy Profile of AJOVY® (fremanezumab) Shared at 7th European Academy of Neurology Congress21.6.2021 14:01:00 CEST | Press release

A new analysis presented by Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on AJOVY® (fremanezumab) injection for the preventive treatment of migraine, indicates to the European neurology community that the medicine has a positive safety profile in relation to risk of cardiovascular events. The data, drawn from an analysis of three published Phase 3 studies of fremanezumab and presented at the 7th Congress of the European Academy of Neurology (EAN), showed minimal changes in the heart rate and blood pressure of those patients studied over a 12 week period. 1 “As a CGRP inhibitor, fremanezumab has been shown to provide protection against migraine in suitable patients, and we remain focused on continued assessment of the safety profile of this therapy, particularly in relation to heart-related issues as it is believed CGRP itself acts as a ‘safeguard’ during cardiovascular ischemia and other events,” said Dr Joshua M. Cohen, Senior Director and Global Therapeutic Area Lead, Mi

Ezbob Introduces New SaaS Platform to Meet the Changing Landscape of Digital Banking21.6.2021 11:00:00 CEST | Press release

Ezbob Ltd., an innovator in customer acquisition technology for financial services, today announced the introduction of a new modular SaaS platform that addresses key trends in the sector. The company’s Ezbob Express™, focuses on three important needs: offering financial service providers the flexibility of filling gaps in their digital transformation strategies, enabling them to make more precise complex credit and risk decisions in real-time, and facilitating the growth of embedded finance. Ezbob’s new Express customer acquisition platform has a modular approach, enabling financial institutions with gaps in their digital channel to add the functionality needed to achieve a customised digital experience. The new modules include: UX & Process Design, Compliance & Authentication, Credit & Risk Decisioning and Product Recommender. Since its inception Ezbob has been providing digital onboarding services for many well-known financial institutions including Santander, NatWest, Metro Bank, P

Ambarella Expands Security AI Vision SoC Portfolio With Two New Families; Doubles Resolution to 32MP30 for 4K Multi-Imager Cameras With Advanced AI21.6.2021 11:00:00 CEST | Press release

Ambarella, Inc. (NASDAQ: AMBA), an AI vision silicon company, today announced the expansion of its AI vision SoC portfolio with the new CV5S and CV52S security families. Based on the CVflow® architecture and advanced 5nm process technology, the new SoCs support simultaneous 4K encoding and advanced AI processing in a single low-power design, which provides industry-leading edge AI SoC performance per watt. The CV5S family is ideal for security camera applications that require multiple sensors for 360-degree coverage, over a wide area and with a long range, such as outdoor city environments or large buildings. The CV52S family is designed for single-sensor security cameras with advanced AI performance that need to more clearly identify individuals or objects in a scene, including faces and license plate numbers over long distances, such as ITS traffic cameras. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005178/en/ Am

Jardiance ® (empagliflozin) approved in Europe for the treatment of heart failure with reduced ejection fraction21.6.2021 10:36:00 CEST | Press release

The European Commission has granted marketing authorization for Jardiance® (empagliflozin) as a treatment for adults with symptomatic chronic heart failure with reduced ejection fraction (systolic heart failure), Boehringer Ingelheim and Eli Lilly and Company have announced.The extension of the indication follows a positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) on 20 May 2021.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005298/en/ “Today’s approval provides an important new treatment option which can now help the millions of people in Europe living with symptomatic chronic heart failure with reduced ejection fraction,” said Faiez Zannad, M.D., Ph.D., EMPEROR Program clinical investigator and Emeritus Professor of Therapeutics at the University of Lorraine, France. “New treatment options such as empagliflozin can save lives and help people spend less time in the hospital and mor

SK Capital Reaches Agreement to Sell Niacet for $1,015m21.6.2021 10:00:00 CEST | Press release

An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it reached agreement to sell Niacet Corp. (“Niacet”) to Kerry Group plc, the global taste and nutrition company, for $1,015m (€853m¹) on a cash-free, debt-free basis, subject to customary closing adjustments. Following the acquisition, Niacet will be integrated into Kerry’s global food protection and preservation platform. Jack Norris, Managing Director at SK Capital, said, “SK Capital is privileged to have partnered with Kelly Brannen and the entire Niacet team. We are proud and appreciative of Niacet’s accomplishments over the last four years leveraging the strong foundation the Brannen family built over many decades. We believe Niacet is well-positioned to continue this growth and flourish under Kerry’s ownership. We wish Kerry and all the employees of Niacet every success.” Kelly Brannen, CEO and significant minority owner of Niacet, commented, “We are proud of the rich heritage we have bui

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom